Qure.ai Secures $65 Million in Funding to Advance AI-Driven Medical Diagnostics

Mumbai-based Qure.ai Raises $65M to Accelerate AI-Driven Medical Diagnosis

The startup has over 1 billion training datasets and is serving more than 90 countries. Indian startup Qure.ai has secured $65 million in funding from investors, led by Lightspeed Venture Partners and 360 ONE Asset Management. The fresh capital will be used to expand and further develop its AI-powered solutions, aimed at enhancing disease detection and improving healthcare outcomes. The startup was founded in 2016 by Prashant Warier. Qure.ai is leveraging AI to help with medical diagnosis and help in detecting health conditions including brain trauma and chest diseases such as lung cancer. Qure.ai's automated medical imaging tools accelerate diagnosis times, allowing physicians to triage cases more efficiently, particularly in urgent situations. This enables healthcare providers to identify critical conditions within minutes instead of hours, helping prevent fatalities and enhancing patient care. In environments where skilled specialists are scarce, Qure's technology serves as a primary screening tool for various infections and non-communicable diseases. Qure.ai's chest CT AI tool, qCT LN Quant, recently received FDA clearance, marking a significant advancement in lung cancer care. The AI tool enables precise tracking of lung nodules on chest CT scans over time, complementing other solutions like qXR-LN for chest X-ray nodule detection and qTrack for follow-up management. Together, these tools enhance early detection and improve patient outcomes. Qure.ai has a total of 16 FDA clearances till date. A couple of years ago, the startup raised $40 million in a funding round led by Novo Holdings and HealthQuad, supported by existing investor MassMutual Ventures. A number of tech companies are leveraging AI for medical diagnosis. A startup named RapidAI works on neurovascular and vascular AI-enhanced clinical decision support and patient workflow. It received an FDA approval for its ICH (intracranial haemorrhage) model, making it the first in the world to get a specificity of 100%. A few months ago, Google's Med-Gemini model achieved 91.1% accuracy in medical diagnostics. Similarly, Microsoft has also been leading initiatives to bridge the healthcare gap in rural India with products such as HoloLens.

Qure Bags $65 Mn To Build AI-Based Products For Disease Detection

Founded in 2016 by Prashant Warier, Qure.ai uses artificial intelligence assistance for medical imaging diagnostics. Essentially, it uses AI to detect brain trauma, chest diseases, among others Medtech startup Qure.ai has reportedly raised $65 Mn (INR 543 Cr) in a Series D funding round co-led by Lightspeed Venture Partners and 360 ONE Asset Management. The round also saw participation from Merck Global Health Innovation Fund and Kae Capital, along with existing investors Novo Holdings, Health Quad and TeamFund. As per a Bloomberg report, it plans to use the fresh proceeds to expand in the US and other markets, improve its GenAI foundation models, and fund acquisitions. With this funding, it will focus on developing its AI-based products to aid in disease detection. This comes a week after Inc42 reported that the startup is looking to raise $50-60 Mn in a funding exercise to be led by Lightspeed. Founded in 2016 by Prashant Warier, Qure.ai uses artificial intelligence assistance for medical imaging diagnostics. Essentially, it uses AI to detect brain trauma, chest diseases, among others. The company claimed that its algorithm can detect clinically relevant abnormal trauma from X-rays, CT Scans and MRIs in a fraction of the time that doctors typically take. The Mumbai-based company is backed by marquee names like Fractal Analytics and Sequoia Capital. Prashant Warier, Qure.AI's cofounder and chief executive officer, told Bloomberg that AI is helping overcome healthcare bottlenecks. The technology is increasingly being used in areas such as drug discovery, patient management in hospitals, and surgical robotics. India's medtech industry is undergoing a significant transformation driven by digital health adoption, AI integration, and the rise of wearable technology. AI is revolutionising medical diagnostics and treatment, with startups and large firms investing heavily in this space. For instance, last month, medtech startup SigTuple raised $4 Mn (over INR 33.5 Cr) in an extended Series C funding round led by Sidbi Venture Capital to ramp up its product portfolio and expansion efforts. In the same month, online healthcare service provider Visit Health secured INR 250 Cr (nearly $29.8 Mn) from PB Fintech's arm, Docprime Technologies, through a mix of capital infusion and secondary share purchase. Meanwhile, healthtech unicorn Innovaccer was in talks with the US-based health and insurance major Kaiser Permanente to raise a funding in the range of $200 Mn-$250 Mn, in a mix of primary and secondary capital.

Lightspeed leads $65 million round by India AI diagnostics startup Qure AI

Indian startup Qure.AI raised $65 million from investors led by Lightspeed Venture Partners and 360 ONE Asset Management, gaining funds to expand and develop its products that use artificial intelligence to help detect diseases. Merck & Co.'s Merck Global Health Innovation Fund and Kae Capital joined the Series D round, along with existing investors including Novo Holdings, Health Quad, and TeamFund, the startup said Monday in a statement. It plans to use the proceeds to expand in the US and other markets, improve its generative AI foundation models and fund acquisitions. The Mumbai-based startup's products use AI to help identify and manage critical diseases at more than 3,000 imaging sites in over 90 countries. The company, founded in 2016, says its solutions outdo human radiologists and physicians in diagnosing conditions like tuberculosis, lung cancer and stroke. Several of its products are cleared for use by US and European Union regulators. AI is helping overcome health care bottlenecks, said Prashant Warier, Qure.AI's co-founder and chief executive officer. The technology is increasingly being used in areas such as drug discovery, patient management in hospitals and surgical robots.

Lightspeed Leads $65 Million Round by India AI Diagnostics Firm

(Bloomberg) -- Indian startup Qure.AI raised $65 million from investors led by Lightspeed Venture Partners and 360 ONE Asset Management, gaining funds to expand and develop its products that use artificial intelligence to help detect diseases. Merck & Co.'s Merck Global Health Innovation Fund and Kae Capital joined the Series D round, along with existing investors including Novo Holdings, Health Quad, and TeamFund, the startup said Monday in a statement. It plans to use the proceeds to expand in the US and other markets, improve its generative AI foundation models and fund acquisitions. The Mumbai-based startup's products use AI to help identify and manage critical diseases at more than 3,000 imaging sites in over 90 countries. The company, founded in 2016, says its solutions outdo human radiologists and physicians in diagnosing conditions like tuberculosis, lung cancer and stroke. Several of its products are cleared for use by US and European Union regulators. AI is helping overcome health care bottlenecks, said Prashant Warier, Qure.AI's co-founder and chief executive officer. The technology is increasingly being used in areas such as drug discovery, patient management in hospitals and surgical robots.

Lightspeed Leads $65 Million Round by India AI Diagnostics Firm

Indian startup Qure.AI raised $65 million from investors led by Lightspeed Venture Partners and 360 ONE Asset Management, gaining funds to expand and develop its products that use artificial intelligence to help detect diseases. Merck & Co.'s Merck Global Health Innovation Fund and Kae Capital joined the Series D round, along with existing investors including Novo Holdings, Health Quad, and TeamFund, the startup said Monday in a statement. It plans to use the proceeds to expand in the US and other markets, improve its generative AI foundation models and fund acquisitions.